LMTK2 Antibody

Introduction to LMTK2 and Its Antibodies

LMTK2, despite its nomenclature suggesting tyrosine kinase activity, functions predominantly as a serine/threonine kinase involved in diverse cellular processes . A genome-wide association study identified LMTK2 as a susceptibility gene for prostate cancer, sparking interest in its cellular functions . LMTK2 antibodies have become invaluable tools for investigating this protein's expression, localization, and interactions within various cellular contexts.

LMTK2 antibodies comprise a diverse category of immunological reagents designed specifically to bind to and detect LMTK2 protein in biological samples. These antibodies are generated against specific epitopes or regions of the LMTK2 protein and are available in various formats including monoclonal and polyclonal variants with different host species origins.

Types and Properties of LMTK2 Antibodies

LMTK2 antibodies are classified based on clonality, host species, target epitopes, and modifications. The table below summarizes key features of commercially available LMTK2 antibodies:

Each antibody is designed to recognize specific epitopes within the LMTK2 protein structure. For example, the monoclonal antibody H00022853-M02 targets amino acids 1181-1280 of human LMTK2 , while the A06144 antibody was raised against a synthesized peptide from the region spanning amino acids 651-700 .

Applications of LMTK2 Antibodies in Research

LMTK2 antibodies find utility across multiple experimental techniques, enabling researchers to investigate this protein's expression, localization, and functional roles.

Western Blotting

Western blot applications remain the most common use for LMTK2 antibodies, with recommended dilutions typically ranging from 1:500 to 1:2000 . In this technique, antibodies detect LMTK2 protein separated by electrophoresis, typically appearing at approximately 250 kDa. Positive detection has been confirmed in various cell lines including HeLa, HepG2, U2OS, and BV-2 .

Immunohistochemistry and Immunofluorescence

LMTK2 antibodies have proven effective in both paraffin-embedded and frozen tissue sections. For immunohistochemistry applications, typical working dilutions range from 1:100 to 1:300 . These applications have been particularly valuable in neurodegenerative disease research, where decreased LMTK2 immunolabeling has been observed in Alzheimer's disease neurons compared to age-matched controls .

ELISA Applications

Both standard and sandwich ELISA techniques utilize LMTK2 antibodies, with the H00022853-M02 monoclonal antibody demonstrating a detection limit of approximately 0.1 ng/ml for recombinant GST-tagged LMTK2 when used as a capture antibody .

Neurodegenerative Diseases

LMTK2 antibodies have been instrumental in elucidating the role of LMTK2 in neurodegenerative conditions. Chromogenic and fluorescent LMTK2 immunohistochemistry on post-mortem brain tissues revealed decreased LMTK2 immunopositivity in neurons of Alzheimer's disease patients compared to both control subjects and those with neocortical Lewy body disease .

In these studies, LMTK2 immunopositivity was limited to neuronal cytoplasm, with neurons (including tau-positive tangle-bearing ones) showing decreased labeling in Alzheimer's disease across all cortical layers . Digital image analysis measuring gray scale signal intensity confirmed significant differences between control subjects and Alzheimer's disease patients, with a moderate decrease also observed in neocortical Lewy body disease, potentially due to coexisting Alzheimer's pathology .

Cancer Research

LMTK2 antibodies have been utilized in cancer research following the identification of LMTK2 as a susceptibility gene for prostate cancer . Immunohistochemical analysis using LMTK2 antibodies has been performed on ovarian cancer samples, demonstrating the utility of these reagents in oncological investigations .

Research has implicated LMTK2 in the regulation of TGFβ-induced Smad2 signaling, a pathway with significant cancer relevance. Studies using LMTK2 antibodies showed that siRNA knockdown of LMTK2 inhibits Smad2 phosphorylation, nuclear accumulation, and transcriptional activity in response to TGFβ stimulation . Given that some anti-oncogenic effects of TGFβ are mediated by expression of cyclin-dependent kinase inhibitory proteins, these findings suggest potential implications for cancer biology .

Molecular Mechanisms Elucidated Using LMTK2 Antibodies

LMTK2 antibodies have been crucial in unraveling several key molecular pathways involving this kinase. One significant pathway identified through such research is LMTK2's regulation of kinesin light chain-2 (KLC2) phosphorylation by glycogen synthase kinase-3β (GSK3β) .

In this pathway, LMTK2 signals via protein phosphatase-1C (PP1C) to increase inhibitory phosphorylation of GSK3β on serine-9, which reduces KLC2 phosphorylation . This promotes binding of Smad2, a known KLC2 cargo protein required for TGFβ signaling . Specifically:

1. LMTK2 interacts with PP1C through a specific binding motif (valine-threonine-phenylalanine; residues 1325-1327 in mouse LMTK2)

2. This interaction leads to increased inhibitory phosphorylation of GSK3β on serine-9

3. Inhibited GSK3β results in reduced KLC2 phosphorylation

4. Reduced KLC2 phosphorylation promotes binding of cargo proteins, including Smad2

5. Enhanced Smad2 binding to KLC2 facilitates TGFβ-induced Smad2 signaling

These mechanisms were elucidated through experiments combining LMTK2 antibodies with other techniques such as immunoprecipitation, siRNA knockdown, and phosphorylation assays.

Technical Considerations for LMTK2 Antibody Usage

Successful application of LMTK2 antibodies requires attention to several technical factors:

Dilution Optimization

Optimal working dilutions vary by application:

• Western blotting: 1:500-1:2000

• Immunohistochemistry: 1:100-1:300

• Immunofluorescence: 1:200-1:1000

• ELISA: 1:20000

Each new experimental system requires titration of the antibody to determine optimal conditions.

Validation Approaches

Proper validation of LMTK2 antibodies typically includes:

• Positive controls (known LMTK2-expressing cell lines or tissues)

• Negative controls (samples with low or no LMTK2 expression)

• Validation across multiple applications (WB, IHC, IF)

• Specificity confirmation through siRNA knockdown experiments

Future Directions in LMTK2 Antibody Research

Emerging research directions utilizing LMTK2 antibodies include:

Therapeutic Targeting

Recent studies have identified decreasing LMTK2 expression during disease progression in various pathologies , suggesting potential therapeutic relevance. LMTK2 antibodies will be crucial for validating the efficacy of interventions targeting this pathway.

Biomarker Development

The differential expression of LMTK2 in disease states, particularly neurodegenerative conditions, suggests potential utility as a biomarker. LMTK2 antibodies may facilitate the development of diagnostic assays to detect altered LMTK2 expression or localization in patient samples.

Pathway Mapping

Continuing investigation of LMTK2's interaction partners and signaling mechanisms will rely heavily on high-quality, well-characterized antibodies. Differential gene expression analysis has revealed global downregulation of LMTK2 associated with changes in the expression of genes like CDK6, OLR1, TOR1B, CHCHD1, and CREG1 , suggesting broader regulatory networks requiring further exploration.